Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Eyepoint Pharmaceuticals Inc (EYPT)
Eyepoint Pharmaceuticals Inc (EYPT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,318,072
  • Shares Outstanding, K 47,074
  • Annual Sales, $ 41,400 K
  • Annual Income, $ -102,250 K
  • 60-Month Beta 1.67
  • Price/Sales 24.82
  • Price/Cash Flow N/A
  • Price/Book 16.67
Trade EYPT with:

Options Overview Details

View History
  • Implied Volatility 101.86% ( +5.76%)
  • Historical Volatility 54.23%
  • IV Percentile 62%
  • IV Rank 17.54%
  • IV High 406.22% on 11/15/23
  • IV Low 37.11% on 04/04/23
  • Put/Call Vol Ratio 1.29
  • Today's Volume 360
  • Volume Avg (30-Day) 1,682
  • Put/Call OI Ratio 1.10
  • Today's Open Interest 33,290
  • Open Int (30-Day) 28,974

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.60
  • Number of Estimates 3
  • High Estimate -0.40
  • Low Estimate -0.76
  • Prior Year -0.61
  • Growth Rate Est. (year over year) +1.64%

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.63 +9.25%
on 02/23/24
30.99 -9.65%
on 02/08/24
-0.51 (-1.79%)
since 02/01/24
3-Month
17.31 +61.76%
on 12/04/23
30.99 -9.65%
on 02/08/24
+21.39 (+323.60%)
since 12/01/23
52-Week
2.21 +1,166.97%
on 03/24/23
30.99 -9.65%
on 02/08/24
+24.83 (+783.28%)
since 03/01/23

Most Recent Stories

More News
Why Shares of EyePoint Pharmaceuticals Were Rising Monday

The company reported positive trial data for its lead therapy to treat two different eye conditions.

AMD : 202.64 (+5.25%)
EYPT : 28.00 (+2.90%)
R&D Activities for Treating Dry Eye Syndrome Resulting in Promising Pipeline of Treatments

EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:NVS),(NASDAQ:ALDX),(NASDAQ:OCUL),(NASDAQ:EYPT) EQNX::TICKER_END

OKYO : 1.4600 (+9.77%)
OKYO.LN : 1.400 (-24.32%)
NVS : 102.06 (+1.08%)
ALDX : 4.22 (+16.57%)
OCUL : 10.75 (+6.86%)
EYPT : 28.00 (+2.90%)
R&D Activities for Treating Dry Eye Syndrome Resulting in Promising Pipeline of Treatments

/PRNewswire/ -- The Global Dry Eye Syndrome market is witnessing continued growth due to the factors such as the growing demand for effective treatments, the...

OKYO : 1.4600 (+9.77%)
NVS : 102.06 (+1.08%)
ALDX : 4.22 (+16.57%)
OCUL : 10.75 (+6.86%)
EYPT : 28.00 (+2.90%)
S&P Futures Muted as Mixed Earnings Weigh on Sentiment, PMI Data in Focus

June S&P 500 futures (ESM23) are trending up +0.07% this morning after three major U.S. benchmark indices finished the regular session in the red as investors assessed a mixed slate of corporate earnings...

ESM23 : 4,453.35s (+0.61%)
TSLA : 202.64 (+0.38%)
T : 16.98 (+0.30%)
AXP : 219.66 (+0.11%)
LRCX : 981.53 (+4.61%)
PG : 158.85 (-0.06%)
HCA : 311.98 (+0.09%)
SLB : 49.35 (+2.11%)
RIO.L.EB : 5,127.000 (+0.59%)
EL.P.DX : 197.710 (+0.53%)
WISH : 6.54 (+0.62%)
CSX : 38.23 (+0.76%)
Strength Seen in EyePoint Pharmaceuticals (EYPT): Can Its 9.6% Jump Turn into More Strength?

EyePoint Pharmaceuticals (EYPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength...

EYPT : 28.00 (+2.90%)
LQDA : 14.52 (+2.54%)
Strength Seen in Acadia (ACAD): Can Its 5.0% Jump Turn into More Strength?

Acadia (ACAD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down...

ACAD : 24.01 (+3.31%)
EYPT : 28.00 (+2.90%)
Down -32.42% in 4 Weeks, Here's Why You Should You Buy the Dip in EyePoint Pharmaceuticals (EYPT)

EyePoint Pharmaceuticals (EYPT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts...

EYPT : 28.00 (+2.90%)
EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Tops Revenue Estimates

EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of 3.17% and 8.48%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?...

EYPT : 28.00 (+2.90%)
LCTX : 1.1100 (+6.73%)
EyePoint and Rallybio Announce Research Collaboration to Evaluate Rallybio’s Inhibitor of Complement Component 5 (C5) and EyePoint’s Proprietary Durasert® Technology for Sustained Intraocular Delivery in Geographic Atrophy

EyePoint Pharmaceuticals, Inc., a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, and Rallybio Corporation (NASDAQ: RLYB),...

RLYB : 2.36 (+1.51%)
EYPT : 28.00 (+2.90%)
EYEPOINT SHAREHOLDER NOTICE: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Eyepoint To Contact Him Directly To Discuss Their Options

/PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against EyePoint Pharmaceuticals ("Eyepoint" or...

EYPT : 28.00 (+2.90%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

EyePoint Pharmaceuticals Inc. operates as a biopharmaceutical company. It engaged in the development of drug devices to treat debilitating diseases of the eye disorders and other chronic conditions. The company's product candidate consists of DEXYCU(TM). EyePoint Pharmaceuticals Inc., formerly known...

See More

Key Turning Points

3rd Resistance Point 30.29
2nd Resistance Point 29.54
1st Resistance Point 28.77
Last Price 28.00
1st Support Level 27.25
2nd Support Level 26.50
3rd Support Level 25.73

See More

52-Week High 30.99
Last Price 28.00
Fibonacci 61.8% 20.00
Fibonacci 50% 16.60
Fibonacci 38.2% 13.20
52-Week Low 2.21

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar